Over the past 12 months, 3 insiders at Kalaris Therapeutics, Inc. filed 3 open-market SEC Form 4 transactions on KLRS: 2 purchases worth $6.2M and 1 sale worth $13K. Insiders have been net buyers over this period. The most recent filing was on May 20, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 20, 26 | Srinivas Akkaraju | BUY | 244.3K | $4.83 | $1.2M |
| Mar 20, 26 | Brett R HagenChief Accounting Officer | SELL | 1.9K | $6.72 | $13K |
| Dec 18, 25 | Samsara Opportunity Fund, L.p.TenPercentOwner | BUY | 479.8K | $10.42 | $5.0M |
| Mar 26, 25 | Brett R HagenChief Accounting Officer | SELL | 907 | $8.97 | $8K |
Over the past 12 months, insiders at Kalaris Therapeutics, Inc. filed 2 open-market purchases worth $6.2M and 1 sale worth $13K on KLRS, which makes them net buyers over the period. The most recent Form 4 was filed on May 20, 26.
The largest recent open-market KLRS insider purchase in our data was $5.0M by Samsara Opportunity Fund, L.p., TenPercentOwner, filed on Dec 18, 25.
3 different insiders at Kalaris Therapeutics, Inc. filed open-market SEC Form 4 transactions on KLRS over the last 12 months.
InsiderTape plots every KLRS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Kalaris Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →